[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2002211490A1 - Compositions and methods of using capsid protein from flaviviruses and pestiviruses - Google Patents

Compositions and methods of using capsid protein from flaviviruses and pestiviruses

Info

Publication number
AU2002211490A1
AU2002211490A1 AU2002211490A AU1149002A AU2002211490A1 AU 2002211490 A1 AU2002211490 A1 AU 2002211490A1 AU 2002211490 A AU2002211490 A AU 2002211490A AU 1149002 A AU1149002 A AU 1149002A AU 2002211490 A1 AU2002211490 A1 AU 2002211490A1
Authority
AU
Australia
Prior art keywords
pestiviruses
flaviviruses
compositions
methods
capsid protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211490A
Inventor
David B. Weiner
Joo-Sung Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU2002211490A1 publication Critical patent/AU2002211490A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
AU2002211490A 2000-10-04 2001-10-04 Compositions and methods of using capsid protein from flaviviruses and pestiviruses Abandoned AU2002211490A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23788500P 2000-10-04 2000-10-04
US60/237,885 2000-10-04
PCT/US2001/031355 WO2002028165A2 (en) 2000-10-04 2001-10-04 Compositions and methods of using capsid protein from flaviviruses and pestiviruses

Publications (1)

Publication Number Publication Date
AU2002211490A1 true AU2002211490A1 (en) 2002-04-15

Family

ID=22895647

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2002211490A Abandoned AU2002211490A1 (en) 2000-10-04 2001-10-04 Compositions and methods of using capsid protein from flaviviruses and pestiviruses
AU2002211524A Ceased AU2002211524B2 (en) 2000-10-04 2001-10-04 Highly expressible genes
AU1152402A Pending AU1152402A (en) 2000-10-04 2001-10-04 Highly expressible genes

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2002211524A Ceased AU2002211524B2 (en) 2000-10-04 2001-10-04 Highly expressible genes
AU1152402A Pending AU1152402A (en) 2000-10-04 2001-10-04 Highly expressible genes

Country Status (7)

Country Link
US (4) US6733994B2 (en)
EP (2) EP1328653B1 (en)
JP (2) JP2004510714A (en)
CN (1) CN1549730A (en)
AU (3) AU2002211490A1 (en)
CA (2) CA2424216A1 (en)
WO (2) WO2002029088A2 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708526D0 (en) * 1997-04-25 1997-06-18 Royal Free Hosp School Med Eukaryotic gene expression cassette and uses thereof
AU2002309508A1 (en) * 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides
EP1397386B1 (en) * 2001-05-25 2009-10-21 The Trustees of The University of Pennsylvania Chimeric proteins for cell targeting and apoptosis induction and methods of using the same
DK1857122T3 (en) 2001-06-05 2011-03-21 Curevac Gmbh Stabilized mRNA with increased G / C content, encoding a viral antigen
CA2452545C (en) * 2001-07-27 2015-06-09 Wyeth West nile vaccine comprising live attenuated, inactivated or killed whole or subunit west nile virus
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
WO2004000217A2 (en) * 2002-06-20 2003-12-31 The Trustees Of The University Of Pennsylvania Vaccines for suppressing ige-mediated allergic disease and methods for using the same
DE10260805A1 (en) 2002-12-23 2004-07-22 Geneart Gmbh Method and device for optimizing a nucleotide sequence for expression of a protein
EP1454988A1 (en) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
CA2793127A1 (en) * 2003-11-12 2005-05-26 Bayer Healthcare Llc Oligonucleotides and methods for detection of west nile virus
EP1766073A4 (en) * 2004-06-04 2007-08-01 Wyeth Corp Enhancing protein expression
WO2006011966A1 (en) * 2004-06-30 2006-02-02 Allergan, Inc. Optimizing expression of active botulinum toxin type e
AU2005271372B2 (en) * 2004-08-04 2012-05-03 Allergan, Inc. Optimizing expression of active botulinum toxin type A
DE102004042546A1 (en) * 2004-09-02 2006-03-09 Curevac Gmbh Combination therapy for immune stimulation
TWI294036B (en) * 2005-02-24 2008-03-01 Tzu Chi Buddhist General Hospital A method for screening compounds against flaviviruses infection by using persistent virus-infected cell systems
EP2392587B1 (en) 2006-03-10 2016-05-04 Peptcell Limited Peptide sequences and compositions
IL176377A0 (en) * 2006-06-18 2006-10-05 Ariella Oppenheim Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders
JP6199533B2 (en) 2006-07-13 2017-09-20 インスティチュート フォー アドバンスド スタディ Viral inhibitory nucleotide sequences and vaccines
EP2594576B1 (en) * 2006-07-28 2015-07-01 The Trustees of The University of Pennsylvania Improved HIV vaccines
US20090035815A1 (en) * 2007-06-29 2009-02-05 Laxmi Srinivas Rao Synthetic Gene for Enhanced Expression in E. Coli
EP2221368B1 (en) * 2007-11-07 2014-03-26 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases West nile virus vaccine, and method for production thereof
CA2705461A1 (en) 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Vaccines against multiple subtypes of influenza virus
CA2708668C (en) * 2008-01-11 2019-03-05 Vgx Pharmaceuticals, Llc Vaccines against multiple subtypes of dengue virus
US8715999B2 (en) * 2008-02-08 2014-05-06 Valneva Austria Gmbh Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines
CA2720166A1 (en) 2008-04-04 2009-10-08 David B. Weiner Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
US8126653B2 (en) * 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US7561972B1 (en) 2008-06-06 2009-07-14 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US8401798B2 (en) * 2008-06-06 2013-03-19 Dna Twopointo, Inc. Systems and methods for constructing frequency lookup tables for expression systems
CN102292345B (en) * 2008-11-17 2015-12-02 Vgx药品有限责任公司 Cause the antigen to the immunne response of anti-flavivirus and application method thereof
CN201397956Y (en) * 2009-03-23 2010-02-03 富士康(昆山)电脑接插件有限公司 Electric connector component
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US20110184160A1 (en) * 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
AU2011264879B2 (en) * 2010-06-11 2015-11-12 Syngenta Participations Ag Compositions and methods for protein production
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
PT3590949T (en) 2010-10-01 2022-08-02 Modernatx Inc Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN104203287B (en) * 2011-07-12 2017-07-14 费城健康及教育公司，d/b/a,德雷克塞尔大学医学院 New difficile dna vaccine
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2707251C2 (en) 2011-10-03 2019-11-25 Модерна Терапьютикс, Инк. Modified nucleosides, nucleotides and nucleic acids and use thereof
US9750795B2 (en) * 2011-12-12 2017-09-05 The Trustees Of The University Of Pennsylvania Proteins comprising MRSA PBP2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections
PL2791160T3 (en) 2011-12-16 2022-06-20 Modernatx, Inc. Modified mrna compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
RS63237B1 (en) 2012-11-26 2022-06-30 Modernatx Inc Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
EP3421046A1 (en) 2014-11-04 2019-01-02 Janssen Vaccines & Prevention B.V. Therapeutic hpv16 vaccines
MX2018002106A (en) 2015-08-20 2018-06-15 Janssen Vaccines & Prevention Bv Therapeutic hpv18 vaccines.
WO2017192418A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
EP3973973A1 (en) 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
JP7385569B2 (en) 2017-12-13 2023-11-22 イノビオ ファーマシューティカルズ，インコーポレイティド Cancer vaccines targeting survivin and their use
BR112020014632A2 (en) * 2018-01-19 2021-01-05 The Wistar Institute Of Anatomy And Biology IMMUNOGENIC COMPOSITION, NUCLEIC ACID MOLECULE ENCODING A PEPTIDE, PEPTIDE, METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST A MCV T ANTIGEN IN A SUBJECT IN NEED OF THE SAME AND FOR TREATING OR PREVENTING THE NEED OF A PATHOLOGY.
KR20220041211A (en) 2019-08-09 2022-03-31 넛크래커 테라퓨틱스 인코포레이티드 Manufacturing methods and apparatus for removing substances from therapeutic compositions
TW202305125A (en) 2021-04-30 2023-02-01 美商凱立凡爾免疫治療股份有限公司 Oncolytic viruses for modified mhc expression
CN113564192B (en) * 2021-08-03 2023-03-14 长春生物制品研究所有限责任公司 Tick-borne encephalitis virus capsid protein C prokaryotic expression vector, recombinant strain and application thereof
US20230084012A1 (en) * 2021-09-14 2023-03-16 Globe Biotech Limited Vaccine for use against coronavirus and variants thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2933693A (en) 1957-05-03 1960-04-19 Lyle R Battersby Sensitivity control circuit
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5254463A (en) 1981-09-18 1993-10-19 Genentech, Inc. Method for expression of bovine growth hormone
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5489529A (en) 1984-07-19 1996-02-06 De Boer; Herman A. DNA for expression of bovine growth hormone
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5206163A (en) * 1985-07-08 1993-04-27 Chiron Corporation DNA encoding bovine diarrhea virus protein
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
ATE174514T1 (en) * 1989-01-23 1999-01-15 Chiron Corp RECOMBINANT CELLS FOR THERAPY OF INFECTIONS AND HYPERPRODELIVERY DISORDERS AND THEIR PRODUCTION
WO1990010693A1 (en) 1989-03-08 1990-09-20 Health Research, Inc. Recombinant poxvirus host selection system
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69027313T2 (en) 1989-03-31 1997-01-23 Univ Washington AVIRULENT PHOP-TYPE MICROORGANISMS CONTAINING VACCINES
ES2070997T3 (en) 1989-12-04 1995-06-16 Akzo Nobel Nv RECOMBINANT HERPES VIRUSES OF TURKEYS AND LIVING VECTOR VACCINES DERIVED FROM THEM.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
EP0527786A1 (en) * 1990-04-03 1993-02-24 Southwest Foundation For Biomedical Research Purified hcv and hcv proteins and peptides
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
GB9209243D0 (en) * 1992-04-29 1992-06-17 Univ Singapore Dengue virus
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
DE9402206U1 (en) * 1994-02-10 1994-05-05 Hydraulik-Ring Antriebs- und Steuerungstechnik GmbH, 72622 Nürtingen Electro proportional solenoid valve unit
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
NL9401820A (en) 1994-11-02 1996-06-03 Meyn Maschf Device for processing poultry suspended from its legs.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6406689B1 (en) * 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US5739972A (en) * 1996-01-02 1998-04-14 Ibm Method and apparatus for positioning a magnetoresistive head using thermal response to servo information on the record medium
CN1216064A (en) * 1996-02-22 1999-05-05 麦克公司 Synthetic HIV genes
ES2374131T3 (en) * 2000-02-16 2012-02-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services AVIRULENT AND IMMUNOGEN CHIMERIC FLAVIVIRUS.
JP2004503233A (en) * 2000-06-16 2004-02-05 インスティティ・パスツール Pro-apoptotic fragment of dengue virus envelope glycoprotein
KR20140137679A (en) 2013-05-23 2014-12-03 삼성전자주식회사 Socket for card

Also Published As

Publication number Publication date
US20090104230A1 (en) 2009-04-23
CA2424216A1 (en) 2002-04-11
EP1328653A2 (en) 2003-07-23
WO2002029088A3 (en) 2002-07-18
WO2002029088A9 (en) 2003-02-20
AU1152402A (en) 2002-04-15
CN1549730A (en) 2004-11-24
EP1322338A2 (en) 2003-07-02
EP1328653B1 (en) 2012-08-01
WO2002028165A3 (en) 2002-08-08
US20050226849A1 (en) 2005-10-13
JP2004510440A (en) 2004-04-08
JP4472250B2 (en) 2010-06-02
WO2002028165A2 (en) 2002-04-11
US20020164349A1 (en) 2002-11-07
EP1328653A4 (en) 2005-07-20
US20020123099A1 (en) 2002-09-05
WO2002029088A2 (en) 2002-04-11
US7348138B2 (en) 2008-03-25
JP2004510714A (en) 2004-04-08
CA2425152A1 (en) 2002-04-11
US6733994B2 (en) 2004-05-11
EP1322338A4 (en) 2005-04-13
AU2002211524B2 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
AU2002211490A1 (en) Compositions and methods of using capsid protein from flaviviruses and pestiviruses
IL153020A0 (en) Methods and compositions for treating flaviviruses and pestiviruses
AU2002230831A1 (en) Compositions of human proteins and method of use thereof
EP1283707A4 (en) Polymerizable compositions and methods of use
AU2002259130A1 (en) Agents for treatment of hcv and methods of use
EP1420767A4 (en) Compositions containing itraconazole and their preparation methods
AU2001273074A1 (en) Combinations of ssri and estrogenic agents
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AP2004003075A0 (en) Soy milk compositions and methods of preparation.
AU2002256543A1 (en) Compositions containing heteropolymers and methods of using same
IL154756A0 (en) Methods and compositions for promoting the maturation of monocytes
AU2001247196A1 (en) Methods and compositions for detection of disease
AU2756301A (en) Compositions comprising genome segments and methods of using the same
AU2002303552A1 (en) Methods and compositions for prevention of angioproliferation
AU2001297556A1 (en) 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
AU2001271801A1 (en) Compositions and methods for producing recombinant virions
AU2001253469A1 (en) Compositions and methods for stabilizing modified tissue
AU2002210887A1 (en) Methods of and pharmaceutical compositions for improving implantation of embryos
AU2002355432A1 (en) Kavalactone compositions and methods of use
IL160138A0 (en) Compositions and methods for modulation of viral maturation
AU2001297794A1 (en) Methods and compositions of human proteins and uses thereof.
AU2001242019A1 (en) Compositions and methods for use thereof in modifying the genomes of microorganisms
AUPQ876400A0 (en) Compositions and method of using them
AU2001251467A1 (en) Methods of making models, methods of using models of murg, compounds that bind, inhibit or stimulate muret proteins, and therapeutic compositions thereof
AU2002316348A1 (en) Chimeric capsid proteins and uses thereof